Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: A1C is associated with diabetes complications but does not reflect glycemic variability (GV), which may worsen outcomes by inducing inflammation, oxidative stress, and cardiac arrhythmias. We tested whether a glucagon-like peptide 1 agonist-based regimen can reduce GV and cardiometabolic risk markers while maintaining similar A1C levels in people with insulin-requiring type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS: After run-in on metformin and basal-bolus insulin (BBI), 102 participants continued metformin and basal insulin and were randomized to exenatide dosing before the two largest meals (glucacon-like peptide-1 receptor agonist and insulin [GLIPULIN group]) or continuation of rapid-acting insulin analogs (BBI group). Indices of GV by continuous glucose monitoring (CGM), hypoglycemia, weight, risk markers, and cardiac arrhythmias were assessed. The primary end point was change in glucose coefficients of variation (CV) by CGM from baseline to 26 weeks. RESULTS: At randomization, the median A1C was 7.3% (57 mmol/mol) for GLIPULIN and 7.4% (56.3 mmol/mol) for BBI, and glucose CVs were 30.3 for BBI and 31.9 for GLIPULIN. At 26 weeks, A1C levels were similar (7.1% [54 mmol/mol] vs. 7.2% [55 mmol/mol]), whereas mean CV improved with GLIPULIN (−2.4 vs. 0.4, P = 0.047). Other GV indices followed similar nonsignificant patterns of improvement with GLIPULIN. There were no differences in hypoglycemic events during CGM or arrhythmias during electrocardiographic monitoring. On-trial changes in body weight (−4.8 kg vs. +0.7 kg, P < 0.001), alanine aminotransferase (P = 0.0002), and serum amyloid A (P = 0.023) favored GLIPULIN. CONCLUSIONS: GLIPULIN reduced GV, weight, and some cardiometabolic risk markers while maintaining equivalent A1C levels versus BBI and might improve clinical outcomes in a larger trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Limited data support the possibility that GV is involved in the pathogenesis of vascular complications of diabetes by inducing inflammatory activation and oxidative stress (52,53).”
From Targets for Glycemic Control (2018) · cites this paper as [52]
In the citing paper
“Despite the improvement in GV, there was no statistically significant difference in cardiac arrhythmias”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
In the citing paper
“They reported that GLP1-RA resulted in significant reductions in GV determined by CGM compared with prandial insulin.”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“26 weeks 45 3,967 (4,197) 1,625 (5,642) 43 2,583 (3,011) 1,113 (3,129) 0.”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Cited by
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390
“diabetes treated with insulin, the means of %CV were approximately the same as the values observed at baseline in the population of the FLAT-SUGAR trial (10,29) using a newer generation of”
MethodResultContinuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Cardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
“Reducing glycemic variability can be achieved [62]; however, whether this reduction would translate into better prognosis in patients with diabetes, it still remains to be demonstrated.”
BackgroundBray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
“They comprised 6749 patients (inflammation evaluated in 6560, oxidative stress in 701 patients), included a median (IQR) study population of 60 (33-122) participants, and had a median (IQR) follow-up of 6 months (84-182 days).”
BackgroundClinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes
Carlson, A. L., Mullen, D. M., & Bergenstal, R. M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0024 · Cited by 177
Glycemic variability in the development of cardiovascular complications in diabetes
Nusca, A., Tuccinardi, D., Albano, M., Cavallaro, C., Ricottini, E., Manfrini, S., Pozzilli, P., & Di Sciascio, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3047 · Cited by 158
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
Glycemic Variability: Risk Factors, Assessment, and Control
Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819826111 · Cited by 124
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
The application of simple metrics in the assessment of glycaemic variability
Monnier, L., Colette, C., & Owens, D. R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.008 · Cited by 106
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
“Interestingly, the FLAT-SUGAR Trial has shown that exenatide on top of long-acting insulin reduced glucose excursions more than a four daily insulin regimen (82).”
Castellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
Bajaj, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H., Aslam, N., Twum-Barima, D., & Aronson, R. (2017) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65
Monnier, L., Colette, C., & Owens, D. R. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101225 · Cited by 63
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Clifton, P. M., Horowitz, M., & Rayner, C. K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13604 · Cited by 58
Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review
Zhang, X., Yang, X. Q., Sun, B., & Zhu, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02896-3 · Cited by 60
Mo, Y., Lu, J., & Zhou, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14112 · Cited by 56
Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies
McGill, J. B., & Ahmann, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0090 · Cited by 49
Breyton, A.-E., Lambert-Porcheron, S., Laville, M., Vinoy, S., & Nazare, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.666008 · Cited by 52
Valente, T., & Arbex, A. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200716201550 · Cited by 53
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 39
Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12884 · Cited by 40
Foreman, Y. D., Brouwers, M. C. G. J., Kallen, C., Pagen, D. M. E., van Greevenbroek, M. M. J., Henry, R. M. A., Koster, A., Wesselius, A., Schaper, N. C., & Stehouwer, C. D. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0385 · Cited by 47
Inpatient Glycemic Variability and Long-Term Mortality in Hospitalized Patients with Type 2 Diabetes
Timmons, J. G., Cunningham, S. G., Sainsbury, C. A. R., & Jones, G. C. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.013 · Cited by 41
CGManalyzer: an R package for analyzing continuous glucose monitoring studies
Zhang, X. D., Zhang, Z., & Wang, D. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx826 · Cited by 38
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Glycemic variability and mortality in patients hospitalized in general surgery wards
Akirov, A., Shochat, T., Dotan, I., Diker‐Cohen, T., Gorshtein, A., & Shimon, I. (2019) · Surgery · doi:10.1016/j.surg.2019.02.022 · Cited by 41
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Livingstone, R., Boyle, J. G., & Petrie, J. R. (2020) · Diabetic Medicine · doi:10.1111/dme.13911 · Cited by 34
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.014 · Cited by 30
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 31
Monnier, L., Colette, C., Schlienger, J.-L., Bauduceau, B., & Owens, D. R. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.007 · Cited by 30
Lee, S., Min, K. W., Lee, B., Jeong, I., Yoo, S.-J., Kwon, H., Choi, Y., & Yoon, K. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0203 · Cited by 30
Frías, J. P., Nakhle, S., Ruggles, J. A., Zhuplatov, S., Klein, E., Zhou, R., & Strange, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12763 · Cited by 28
Brown, S. A., Basu, A., & Kovatchev, B. P. (2019) · Diabetic Medicine · doi:10.1111/dme.13944 · Cited by 27
Krämer, A. L., Riederer, A., Fracassi, F., Boretti, F. S., Sieber‐Ruckstuhl, N. S., Lutz, T. A., Contiero, B., Zini, E., & Reusch, C. E. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15915 · Cited by 27
Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
Park, M., & Choi, K. M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0316 · Cited by 30
Wang, J., Li, H.-Q., Xu, X.-H., Kong, X.-C., Sun, R., Jing, T., Ye, L., Su, X.-F., & Ma, J.-H. (2019) · BioMed Research International · doi:10.1155/2019/2682657 · Cited by 23
Dong, X., Chen, C., Geng, Q., Cao, Z., Chen, X., Lin, J.-X., Jin, Y., Zhang, Z., Shi, Y., & Zhang, X. D. (2019) · Entropy · doi:10.3390/e21030274 · Cited by 31
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 24
Cardiovascular Risk Factors: It's Time to Focus on Variability!
Barnett, M. P., & Bangalore, S. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.2.255 · Cited by 25
Li, F.-F., Jiang, L., Fu, L., Zhu, H., Zhou, P., Zhang, D., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0222-7 · Cited by 24
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 27
Aronson, R., Umpierrez, G. E., Stager, W., & Kovatchev, B. P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13580 · Cited by 23
Muo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., et al. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s182953 · Cited by 21
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 21
Glucose variability predicts 6-month mortality in patients hospitalized with acute heart failure
Cunha, F. M., Cidade-Rodrigues, C., Elias, C., Oliveira, D., Bettencourt, P., & Lourenço, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02719-7 · Cited by 21
Ahdab, M. A., Leth, J., Knudsen, T., Vestergaard, P., & Clausen, H. G. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108170 · Cited by 20
Mehta, R., Billings, L. K., Liebl, A., & Vilsbøll, T. (2022) · Diabetic Medicine · doi:10.1111/dme.14901 · Cited by 20
Monnier, L., Colette, C., & Owens, D. R. (2016) · Diabetes Care · doi:10.2337/dc16-1133 · Cited by 19
Boosting GLP-1 by Natural Products
Yaribeygi, H., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73234-9_36 · Cited by 20
Glycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome
Olmo-García, M. I. D., & Merino-Torres, J. F. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109504 · Cited by 15
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?
Monnier, L., Colette, C., & Owens, D. R. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.005 · Cited by 15
Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198652 · Cited by 13
BAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 14
Zhang, L., Sun, X., & Tian, Q. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02241-0 · Cited by 12
Liu, Y., Fu, H., Wang, Y., Sun, J., Zhang, R., Zhong, Y., Yang, T., Han, Y. T., Xiang, Y., Yuan, B., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1546164 · Cited by 12
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
Bolli, G. B., Porcellati, F., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dci20-0038 · Cited by 11
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Gómez, A., Henao, D. C., Taboada, L. B., Fuentes, O., Lucero, O. J. M., Sanko, A. A., Ma, R., Múñoz, Ó., Rondón, M., García-Jaramillo, M., et al. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s288526 · Cited by 10
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 15
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 9
Simental-Mendía, M. A., Linden‐Torres, E., Sánchez‐García, A., Sahebkar, A., & Simental‐Mendía, L. E. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15304 · Cited by 9
Cao, C., Wang, H., Gao, H., & Wu, W. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.949091 · Cited by 9
SKOLNIK, N., Hinnen, D., Kiriakov, Y., MAGWIRE, M. L., & White, J. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0048 · Cited by 9
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Bizino, M. B., Jazet, I. M., van Eyk, H. J., Rensen, P. C. N., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01635-0 · Cited by 7
The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring
Kushner, P. R., & Kruger, D. F. (2020) · Clinical Diabetes · doi:10.2337/cd19-0093 · Cited by 7
Olmo-García, M. I. D., Hervás, D., Caudet-Esteban, J., Martín-Portugués, A. B., Rubio, A. C., Vives, M. Á. A., Catalá-Gregori, A. I., Martínez, M. P., & Merino-Torres, J. F. (2020) · Journal of International Medical Research · doi:10.1177/0300060520926063 · Cited by 7
Wang, L., Liu, X., Yang, W., Lai, J., Yu, X., Liu, J., Gao, X., Ming, J., Ma, K., Xu, J., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00904-z · Cited by 7
CGManalyzer: an R package for analyzing continuous glucose monitoring studies
Zhang, X. D., Zhang, Z., & Wang, D. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty144 · Cited by 7
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026) · PeerJ · doi:10.7717/peerj.20710 · Cited by 6
“5, revealed high heterogeneity among these studies (2012) ; Takeshita et al. (2015) ; Xie et al. (2022) ; Yan et al. (2019) ; The FLAT-SUGAR Trial Investigators (2016) ; Bunck et al. (2010) ; Derosa et al. (2010) ; Forst et al. (2012) ; Li et al. (2019) ; Lin et al. (2015) ; Pastel et al. (2017) ;…”
Chen, J.-J., Hsu, C., Hung, C., Suen, M.-W., Wang, H.-Y., Yang, W.-C., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020608 · Cited by 7
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
CVOTs: What did the endocrinologist learn?
Valensi, P. E., & Prévost, G. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107947 · Cited by 6
Ehrhardt, N. M., Aroda, V. R., Galindo, R. J., Peters, A. L., & Shubrook, J. H. (2023) · Clinical Diabetes · doi:10.2337/cd23-0047 · Cited by 6
Monnier, L., Colette, C., & Owens, D. R. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30058-0 · Cited by 6
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Flash Continuous Glucose Monitoring: A Practical Guide and Call to Action for Pharmacists
Cowart, K., & Zgibor, J. C. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211000273 · Cited by 5
Cañas, J. M. H., Pontificia Universidad Javeriana, B., Gómez-Gutiérrez, M., Pontificia Universidad Javeriana, B., Ossa, A. B., & Pontificia Universidad Javeriana, B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.2.4 · Cited by 6
Heald, A. H., Stedman, M., Warner-Levy, J. J., Belston, L., Paisley, A. N., Patel, R., White, A., Jude, E. B., Gibson, M., Habte‐Asres, H. H., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01648-w · Cited by 5
Continuous Glucose Monitoring in 2016
Bode, B. W., & Battelino, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.2502 · Cited by 6
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Glucose variability and glycated hemoglobin HbA1c in type 1 and type 2 diabetes
Borkowska, A., Szymańska‐Garbacz, E., Kwiecińska, E., Ignaczak, A., & Czupryniak, L. (2017) · Clinical Diabetology · doi:10.5603/dk.2017.0009 · Cited by 4
Riddle, M. C., & Miller, M. E. (2018) · Diabetes Care · doi:10.2337/dci18-0009 · Cited by 4
Xing, Y., Wu, M., Liu, H., Li, P., Pang, G., Zhao, H., & Wen, T. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01269-0 · Cited by 4
Metadata
- Authors
- The FLAT-SUGAR Trial Investigators
- Corresponding author
- The FLAT-SUGAR Trial Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-19
- Volume
- 39
- Issue
- 6
- Pages
- 973-981
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2403039904
- Cited by
- 135
- References
- 21
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 17 · 2020: 11 · 2019: 20 · 2018: 23 · 2017: 20 · 2016: 13
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- Becton Dickenson
- Dexcom
- Medicomp
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, type 2 diabetes, GLP-1 receptor agonists, exenatide, rapid-acting insulin analogs, multiple daily insulin injections, cardiovascular risk, glycemic control, HbA1c, hypoglycemia, cardiac arrhythmias, body weight, cardiometabolic risk markers, serum amyloid A, alanine aminotransferase
- MeSH terms
- Exenatide, Adult, Aged, Alanine Transaminase, Serum Amyloid A Protein, Arrhythmias, Cardiac, Blood Glucose, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Risk Factors, Venoms, Insulin, Short-Acting, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.